An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer.

Prior treatment

• Participants who received systemic immunostimulatory therapy within 4 weeks prior to the first dose.
• Participants who received systemic immunosuppressive therapy within 2 weeks before the first dose.
• Participants with a history of interstitial pneumonia or cannot exclude interstitial pneumonia; or there are other moderate to severe lung diseases that may affect respiratory function. Or received previous pneumonectomy surgery.
• There were clinically significant bleeding symptoms or obvious bleeding tendency within 1 month before the first administration.
• Arterial and venous thrombosis events occurred within 3 months before the first administration.
• Participants with active hepatitis B or C.
  • 1.Evidence of active tuberculosis infection within 1 year before the first administration.
  • 12.Severe infection occurred within 4 weeks before the first administration. 13.History of severe allergic reactions to other monoclonal antibody / fusion protein drugs.
  • 14\. Allergy to any component of the treatment regimen. 15.Participants were known to have a history of psychotropic drug abuse, alcohol abuse or drug abuse.

Other illness

• Participants with active, known or suspected autoimmune diseases.
• Other malignant tumors within 5 years before screening.
• Participants with severe cardiovascular and cerebrovascular diseases.
• HIV test positive.

• voluntarily participate in this clinical study, understand the research procedure and be able to sign the informed consent in writing ;
• At the time of signing the informed consent form, the age is 18-70 years old ( including both ends ), both men and women can.
• The ECOG score was 0 or 1.
• Pathologically confirmed NSCLC, assessed as resectable or previously resected (R0).
• Adequate bone marrow and organ function.